EI
ZVRA icon

EAM Investors’s Zevra Therapeutics ZVRA Stock Holding History

EAM Investors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,828
Closed -$1.22M – 350
2015
Q4 		$1.22M Buy
3,828
+15
+0.4% +$4.07K 0.16% 239
2015
Q3 		$1.18M Buy
+3,813
New +$1.17M 0.19% 241

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

EAM Investors's ZVRA Position: Q1 2016 in Review

EAM Investors sold out of Zevra Therapeutics (ZVRA) in Q1 2016, closing a stake of 3,828 shares — an estimated $1.22M sold.

EAM Investors first reported a position in ZVRA in Q3 2015 and held it in 2 quarters. The position peaked at $1.22M in Q4 2015. 58 funds tracked by Wall St. Rank hold ZVRA as of Q1 2016.

  • EAM Investors reported no remaining Zevra Therapeutics position as of Q1 2016 after selling out during the quarter.
  • EAM Investors sold 3,828 Zevra Therapeutics shares in Q1 2016, an estimated $1.22M.
  • EAM Investors first reported a position in Zevra Therapeutics in Q3 2015 and held it in 2 quarters.
  • EAM Investors's Zevra Therapeutics position peaked at $1.22M in Q4 2015.
  • 58 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2016.

Based on EAM Investors's 13F filing for Q1 2016, filed 16 May 2016.